RBC Capital analyst Randall Stanicky is positive on Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Flexion Therapeutics (FLXN), Jazz Pharmaceuticals (JAZZ) as his top selections in Specialty Pharma, saying the sector has come under particular pressure in the most recent market sell-off. The analyst anticipates Amneal Pharmaceuticals to benefit from a cyclical generics recovery in the 2nd half of 2019, saying its "valuation is compelling against growth outlook". For Endo International, Stanicky sees the cellulite data driven selloff as overdone and believes that its low valuation helps to set a floor for the stock. For Flexion, the analyst anticipates a 2019 inflection on ramping Zilretta launch, adding that its 32% short interest is "hard to ignore". For Jazz Pharma, Stanicky points to a re-set of expectations around Vyxeos in Q3 as the company enters a "catalyst-heavy path led by December 20th solriamfetol PDUFA" and a material discount in valuation. The analyst maintain his Outperform rating on these four stocks.

Amneal Pharmaceuticals announced the availability of Over the Counter, or OTC, Naloxone Hydrochloride, or Naloxone HCI, Nasal Spray, USP, 4mg, following Abbreviated New Drug Application, or ANDA, approval from the FDA. Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC Narcan HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.